Alkem Laboratories Raises its Investment to INR 1036 Cr for Ujjain Manufacturing Facility

The Ujjain unit is expected to manufacture a range of pharmaceutical formulations, including tablets, capsules, and injectables, supporting the company’s growing domestic and global demand.

Alkem Laboratories has increased its planned investment for an upcoming manufacturing facility in Ujjain, Madhya Pradesh, raising the outlay from INR 533 crore to INR 1036 crore, aimed at expanding its footprint.

The revised investment will be deployed in phases and is aimed at expanding the facility’s scope and production capabilities in India.

The Ujjain unit is expected to manufacture a range of pharmaceutical formulations, including tablets, capsules, and injectables, supporting the company’s growing domestic and global demand.

The company has secured approximately 30 acres of land in Ujjain, Madhya Pradesh, through an allotment letter.

The facility is strategically located near the Delhi-Mumbai Industrial Corridor (DMIC) and is expected to offer logistical advantages and support operational efficiencies, aligning with the company’s long-term growth plans.

Once operational, the facility is expected to enhance regional economic development by boosting industry activity in the area as well as generating employment.

The development was disclosed under SEBI listing regulations and communicated to stock exchanges.

Last year, the company’s subsidiary arm, Alkem MedTech, signed a binding offer to acquire Bombay Ortho Industries, a manufacturer of orthopaedic implants.

The move aligned with the company’s strategy to expand its presence in the medical technology sector in India.

Stay tuned for more such updates on Digital Health News